• Mehmet Kanbay, Sidar Copur, Cem Tanriover, Duygu Ucku, and Luke Laffin.
• Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey. Electronic address: mkanbay@ku.edu.tr.
• Eur. J. Intern. Med. 2023 Sep 1; 115: 182818-28.

AbstractThe prevalence of arterial hypertension is approximately 47% in the United States and 55% in Europe. Multiple different medical therapies are used to treat hypertension including diuretics, beta blockers, calcium channel blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, alpha blockers, central acting alpha receptor agonists, neprilysin inhibitors and vasodilators. However, despite the numerous number of medications, the prevalence of hypertension is on the rise, a considerable proportion of the hypertensive population is resistant to these therapeutic modalities and a definitive cure is not possible with the current treatment approaches. Therefore, there is a need for novel therapeutic strategies to provide better treatment and control of hypertension. In this review, our aim is to describe the latest developments in the treatment of hypertension including novel medication classes, gene therapies and RNA-based modalities.Copyright © 2023 European Federation of Internal Medicine. All rights reserved.

21 keywords...

hide…